medigraphic.com
ISSN 2448-8909 (Print)

2023, Number 3

<< Back Next >>

Med Crit 2023; 37 (3)

Effects of vaccination on severe COVID-19 in the Department of Intensive Medicine of the Military Central Hospital

García SR, Morales PII, Rugerio TDA

Language: Spanish
References: 13
Page: 229-234
PDF size: 169.31 Kb.


ABSTRACT

Introduction: the Intensive Medicine Department of the Central Military Hospital became a national reference center for patients with severe and critical COVID-19. The objective is to define the effects of vaccination in severe COVID-19. Material and methods: descriptive, cross-sectional, retrospective study, in records of patients with severe COVID-19 in the period from January 1, 2020 to December 31, 2021, information regarding demographic and clinical characteristics and the state of vaccination to carry out the statistical analysis. Results: 378 cases met the inclusion criteria, 280 men and 98 women; average age 52 years; 326 cases without vaccination, 24 partially vaccinated and 28 fully vaccinated; 266 deaths within 28 days. Conclusion: vaccination against COVID-19 decreases the risk of severe disease in healthy, young people and in men. Arterial hypertension and immunosuppression increase the risk of aggravation of COVID-19 even in the presence of vaccination.


REFERENCES

  1. Kriz C, Imam N, Zaidi S. Breaking down COVID-19: a living textbook. Miami, FL, USA: First Medicine and Global Clinical Partners; 2020.

  2. Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians. Emerg Med Pract. 2020;22(5):1-28.

  3. Gómez Marco JJ, Álvarez Pasquín MJ, Martín Martín S. Efectividad y seguridad de las vacunas para el SARS-CoV-2 actualmente disponibles; FMC. 2021;28(8):442-451.

  4. Arabi YM, Azoulay E, Al-Dorzi HM, Phua J, Salluh J, Binnie A, et al. How the COVID-19 pandemic will change the future of critical care. Intensive Care Med. 2021;47(3):282-291.

  5. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health; 2022. Available in: https://www.covid19treatmentguidelines.nih.gov/

  6. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46(6):1099-1102.

  7. Hajjar LA, Costa IBSDS, Rizk SI, Biselli B, Gomes BR, Bittar CS, et al. Intensive care management of patients with COVID-19: a practical approach. Ann Intensive Care. 2021;11(1):36.

  8. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

  9. Gil R, Bitar P, Dreyse J, Florenzano M, Jorquera J, Joel M, et al. Cuadro clínico del COVID-19. Rev Med Clin Condes. 2021;32(1):20-29.

  10. Menezes MCS, Pestana DVS, Gameiro GR, da Silva LFF, Baron E, Rouby JJ, et al. SARS-CoV-2 pneumonia-receptor binding and lung immunopathology: a narrative review. Crit Care. 2021;25(1):53.

  11. Our World in Data. COVID-19 data explorer. 2022. Available in: https://ourworldindata.org/explorers/coronavirus-data-explorer

  12. Zhu Y, Liu S, Zhang D. Effectiveness of COVID-19 vaccine booster shot compared with non-booster: a meta-analysis. Vaccines (Basel). 2022;10(9):1396.

  13. World Health Organization. Good practice statement on the use of second booster doses fot COVID-19 vaccines. 2022. Available in: https://apps.who.int/iris/bitstream/handle/10665/361714/WHO-2019-nCoV-Vaccines-SAGE-Boosters-2022.1-eng.pdf




2020     |     www.medigraphic.com